This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Uadia, P. Articles by Ghose, T. Search for Related Content PubMed PubMed Citation Articles by Uadia, P. Articles by Ghose, T.

Tumor and Tissue Distribution of a Methotrexate-Anti-EL4 Immunoglobulin Conjugate in EL4 Lymphoma-bearing Mice¹

Departments of Biochemistry [P. U., A. H. B.] and Pathology [T. G.], Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia B3H 4H7, Canada

The uptake and tissue distribution of [³H]methotrexate ([³H]MTX) at doses of 5 mg/kg i.p. either free or linked to anti-EL4 immunoglobulin G (AELG) or normal rabbit globulin (NRG) was studied in EL4 lymphoma-bearing C57BL/6J mice. When the uptakes of MTX-AELG, MTX-NRG, and free MTX were assayed as cell-associated ³H activity, comparison 3 hr after administration showed that uptake of MTX administered as the AELG conjugate was 2.5 times the uptake of MTX administered as the NRG conjugate and 6 times the uptake of MTX administered free. In contrast to the difference in the uptake of MTX-AELG and MTX-NRG by tumor cells, the pattern of uptake in all the other tissues studied was generally similar for the two conjugates. Conjugated MTX persisted in all tissues and serum and ascites fluid, whereas free MTX declined rapidly after reaching peak levels around 1 hr, except in EL4 cells where 45% was retained at 24 hr. The levels of intracellular MTX after administration of these three agents exceeded the intracellular dihydrofolate reductase level and correlated with the relative tumor-inhibitory effect in vivo of the agent (MTX-AELG > MTX-NRG > MTX).

¹ Supported by the Medical Research Council of Canada.

² Recipient of a fellowship from the University of Port Harcourt, Port Harcourt, Nigeria.

³ To whom requests for reprints should be addressed.

Received 12/21/83. Accepted 6/22/84.

This article has been cited by other articles:

				N. Umemoto, Y. Kato, and T. Hara Review : Molecular Design of Methotrexate-Antibody Conjugates for Targeted Cancer Treatment Journal of Bioactive and Compatible Polymers, January 1, 1992; 7(2): 191 - 219. [PDF]